Industry Educational Session - Beyond the ward: ambulatory delivery of CAR T- Sponsored by Bristol Myers Squibb
Tracks
-
| Monday, April 20, 2026 |
| 1:35 PM - 2:20 PM |
| Room 12, Upper Level |
Details
The session objectives are:
• To review the latest long-term outcomes for transplant-eligible R/R LBCL patients
• To examine real-world safety data from the DESCAR-T registry
• To explore considerations and practical approaches relevant to ambulatory CAR T pathway development, including patient selection and site readiness for appropriate patients
This promotional symposium is organised and funded by Bristol Myers Squibb and intended for UK Healthcare Professionals only. Bristol Myers Squibb products will be discussed in this symposium. Prescribing and adverse event reporting information will be available at the meeting.
CAR T, chimeric antigen receptor T-cell; LBCL, large B-cell lymphoma; R/R, relapsed/refractory.
Speaker
Prof. Graham Collins
Speaker One
Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust, specialising in lymphoma and lymphoproliferative disorders. Clinical expert on the National CAR T-cell therapy panel and co-author of NICE national guidelines for Hodgkin's lymphoma and T-cell lymphoma
Surabhi Chaturvedi
Senior Psychotherapist
King's College Hospital NHS Foundation Trust, London, UK
Speaker Two
Counsellor/Psychotherapist – Haemato-Oncology, King's College Hospital NHS Foundation Trust, UK
Kathryn Riley
Leeds Teaching Hospital NHS Trust
Speaker Three
Department of Haematology, Leeds Teaching Hospitals NHS Foundation Trust, UK
Dr Michael Northend
Consultant Haematologist
University College London Hospitals NHS Foundation Trust
Speaker Four
